AI Tech Helps Lumen Bioscience Refine Algae-Based Drug Development

The advent of AI technology has led to numerous, significant victories for healthcare technology, particularly in the area of biologics. Lumen Bioscience, with backing from Google researchers, has made great strides by bringing machine-learning techniques into its large-molecule biologics production.

The company’s objective is to cultivate an ideal environment for the growth of spirulina, an algae that has undergone extensive genetic engineering in order for it to render the desired therapeutic compounds. Spirulina, modified so that its cells reach their full medicinal potential, can be easily packaged into capsules for oral treatment.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The upside of a cheaper alternative that is certainly more convenient to administer than intravenous drugs has caught the eye of the industry. The assistance of Google and financial support from the Bill & Melinda Gates Foundation will allow Lumen to beef up its biomanufacturing capacity. The U.S Department of Energy has also contributed, in the form of a $2 million grant.

Lumen staffers designated their AI technology to mix-and-match a set of 17 variables that affect algae growth. Research showed that machine-learning methodology might be able to lift yield volumes by 70% to 100%.

Going forward, Lumen will use its network of supporters to continue honing its biologic drug processes. Algae dosage is a promising treatment strategy for gastrointestinal disease, including diarrhea, Clostridium difficile infections, and COVID-19 side effects.